Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Receivables - Accured (2023 - 2024)

Roivant Sciences' Receivables - Accured history spans 2 years, with the latest figure at $23.2 million for Q4 2024.

  • For Q4 2024, Receivables - Accured rose 22.68% year-over-year to $23.2 million; the TTM value through Dec 2024 reached $23.2 million, up 22.68%, while the annual FY2024 figure was $23.2 million, 22.68% up from the prior year.
  • Receivables - Accured reached $23.2 million in Q4 2024 per ROIV's latest filing, up from $13.9 million in the prior quarter.
  • In the past five years, Receivables - Accured ranged from a high of $27.4 million in Q1 2024 to a low of $4.9 million in Q1 2023.